NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Tenaya Therapeutics, Inc. (TNYA) Stock Analysis

Tenaya Therapeutics, Inc. (TNYA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TNYA

$0.68

−$0.01 (−1.73%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TNYA with… →

TNYA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.69
Previous Close
$0.70
Day's Range
0.68–0.71
52-Week Range
0.53–2.35
Volume
1.20M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.78
Valuation
Market Cap
$153.19M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
114.75
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.50
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$90.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
224.23M
1-Year Return
−44.92%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
2.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TNYA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.07%
2025−50.21%
2024−55.86%
2023+61.19%
2022−89.39%
2021 (partial year)+23.45%

As of September 4, 2026.

TNYA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$90.60M—
2024$0.00−$111.13M—
2023$0.00−$124.08M—
2022$0.00−$123.67M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$93.33M−$90.60M—
2024$0.00—−$115.95M−$111.13M—
2023$0.00—−$131.19M−$124.08M—
2022$0.00—−$125.62M−$123.67M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TNYA Valuation vs Biotechnology Median

Median of 656 stocks
MetricTNYABiotechnology medianvs median
P/S ratio114.7515.267.5x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tenaya Therapeutics, Inc. (TNYA) at $153.19M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 70.

TNYA last closed at $0.68 on September 4, 2026. That is −$0.01 (−1.73%) against the previous close. Over the past 52 weeks the price has ranged from $0.53 to $2.35. The latest close sits 28.38% above that 52-week low.

Financial Health

In fiscal 2025, Tenaya Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $90.60M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.5.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 114.75. On price-to-sales that is 7.5 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.78. Annualized volatility over the trailing 5 years is 106.07%. The trailing one-year price return is −44.92%. Across 5 years the annualized return works out at −51.18%.

Growth & Income

No dividend is on file for TNYA.

2026 is still running; the price is −4.07% year to date. Across the complete calendar years on file, 2023 returned +61.19% and 2022 returned −89.39%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

Tenaya Therapeutics, Inc. (TNYA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tenaya Therapeutics, Inc. TNYA $153.19M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Tenaya Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit website →